The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
In vivo effects of a GPR30 antagonist
Open accessAbstract
Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30/GPER, in addition to classical nuclear estrogen receptors (ERα/β), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized a selective agonist of GPR30, G-1 (1). To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of a G-1 analog, G15 (2) that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 reveals that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Behavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302
Self-citationCryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Identity of an Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells
Thomas, P., Pang, Y., Filardo, E. J., & Dong, J. (2005) · Endocrinology · doi:10.1210/en.2004-1064 · Cited by 1,407
Filardo, E. J. (2000) · Molecular Endocrinology · doi:10.1210/me.14.10.1649 · Cited by 1,383
Virtual and biomolecular screening converge on a selective agonist for GPR30
Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., Parker, M. A., Tkachenko, S. E., Savchuck, N. P., Sklar, L. A., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio775 · Cited by 818
Self-citationCrystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5998 · Cited by 738
Thomas, P., & Dong, J. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.017 · Cited by 603
Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100518 · Cited by 590
Self-citation
Cited by
Advances in the Chemistry of Tetrahydroquinolines
Sridharan, V., Suryavanshi, P. A., & Menéndez, J. C. (2011) · Chemical Reviews · doi:10.1021/cr100307m · Cited by 1,089
The G-protein-coupled estrogen receptor GPER in health and disease
Prossnitz, E. R., & Barton, M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.122 · Cited by 925
“In 2009, the GPER-selective antagonist G15 ( Figure 1 ) was identified”
BackgroundSelf-citationGillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
“However, pharmacological and emerging ultrastructural evidence demonstrates that classic “nuclear” ER and ER , and probably other novel receptors (such as GPR30; Table 1), can also be localized at the cell membrane to effect rapid activation of intracellular brain signaling pathways and modulatory proteins within seco…”
BackgroundThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Estrogens, Neuroinflammation, and Neurodegeneration
Villa, A., Vegeto, E., Poletti, A., & Maggi, A. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1007 · Cited by 423
“The most investigated synthetic ligands for GPR30 are currently two steroids known as G-1 (agonist) (180) and G-15 (antagonist) (181, 182); both of these ligands can readily cross the BBB.”
BackgroundEstrogen biology: New insights into GPER function and clinical opportunities
Prossnitz, E. R., & Barton, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.02.002 · Cited by 400
Self-citationThe unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360
Mechanisms of estrogen signaling and gene expression via GPR30
Prossnitz, E. R., & Maggiolini, M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.026 · Cited by 346
Self-citationMeyer, M. R., Clegg, D. J., Prossnitz, E. R., & Barton, M. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02237.x · Cited by 332
Self-citationIdentification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity
Dennis, M. K., Field, A. S., Burai, R., Ramesh, C., Petrie, W. K., Bologa, C. G., Oprea, T. I., Yamaguchi, Y., Hayashi, S.-I., Sklar, L. A., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.07.002 · Cited by 311
Self-citationProssnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
Self-citationThe G protein-coupled oestrogen receptor GPER in health and disease: an update
Prossnitz, E. R., & Barton, M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00822-7 · Cited by 231
Self-citationEstrogen regulates Hippo signaling via GPER in breast cancer
Zhou, X., Wang, S., Wang, Z., Feng, X., Liu, P., Lv, X.-B., Li, F., Yu, F.-X., Sun, Y., Yuan, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79573 · Cited by 232
Sharma, G., Hu, C., Brigman, J. L., Zhu, G., Hathaway, H. J., & Prossnitz, E. R. (2013) · Endocrinology · doi:10.1210/en.2013-1357 · Cited by 210
“These differences are corroborated by the GPER-selective ligand G-1, which exerts little estrogenic effect on the uterus in terms of imbibition and epithelial proliferation (58).”
BackgroundSelf-citationEstrogen therapy and cognition: a review of the cholinergic hypothesis
Gibbs, R. B. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0036 · Cited by 206
Pelekanou, V., Kampa, M., Kiagiadaki, F., Deli, A., Theodoropoulos, P., Agrogiannis, G., Patsouris, E., Tsapis, A., Castanas, E., & Notas, G. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0914-430rr · Cited by 184
What have we learned about GPER function in physiology and disease from knockout mice
Prossnitz, E. R., & Hathaway, H. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.06.014 · Cited by 157
“Importantly, the GPER antagonist G15 blocked estrogen-dependent proliferation by about 50% in a dose-dependent manner [39], suggesting that GPER contributes to estrogen-dependent proliferation.”
BackgroundInfluentialSelf-citationG Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“Recently, a selective GPER agonist (G-1) was identified that displays no activity at the estrogen receptors ERa or ERb (Bologa et al., 2006), and selective GPER antagonists have also been discovered (G15 and G36) (Dennis et al., 2009, 2011).”
G‐Protein Oestrogen Receptor 1: Trials and Tribulations of a Membrane Oestrogen Receptor
Srivastava, D. P., & Evans, P. D. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12071 · Cited by 89
Hernández-Silva, C. D., Villegas-Pineda, J. C., & Pereira-Suárez, A. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00544 · Cited by 74
Lv, X., He, C., Huang, C., Hua, G., Wang, Z., Remmenga, S. W., Rodabough, K. J., Karpf, A. R., Dong, J., Davis, J. S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0626 · Cited by 53
GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease
Guan, J., Yang, B., Fan, Y., & Zhang, J. (2017) · Neuroimmunomodulation · doi:10.1159/000478908 · Cited by 53
Samartzis, N., Samartzis, E. P., Noske, A., Fedier, A., Dedes, K. J., Caduff, R., Fink, D., & Imesch, P. (2012) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-10-30 · Cited by 43
“observed that the GPER-specific antagonist G15 was capable of partially inhibiting the estrogendependent proliferation of uterine epithelia [26] and concluded that GPER partially mediates the estrogen-induced proliferative response of the uterine epithelium.”
BackgroundThe role of G protein-coupled estrogen receptor 1 on neurological disorders
Roque, C., Mendes-Oliveira, J., Duarte-Chendo, C., & Baltazar, G. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100786 · Cited by 41
Targeting the G protein-coupled estrogen receptor (GPER) in obesity and diabetes
Sharma, G., & Prossnitz, E. R. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100080 · Cited by 34
Self-citationGilligan, L. C., Gondal, A., Tang, V., Hussain, M. T., Arvaniti, A., Hewitt, A.-M., & Foster, P. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00103 · Cited by 32
Chason, R. J., Kang, J.-H., Gerkowicz, S. A., Dufau, M. L., Catt, K. J., & Segars, J. H. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.023 · Cited by 14
“, 2006), antagonist G15 (Dennis et al., 2009), and siRNA knockdown of GPER1 reveal that GPER1 is at least partly responsible for rapid excitatory E2 action (Kenealy and Terasawa, 2012).”
BackgroundInfluentialLiu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07005-0 · Cited by 13
Metadata
- Authors
- Dennis, M. K., Burai, R., Ramesh, C., Petrie, W. K., Alcon, S. N., Nayak, T. K., Bologa, C. G., Leitao, A., Brailoiu, E., Deliu, E., Dun, N. J., Sklar, L. A., Hathaway, H. J., Arterburn, J. B., Oprea, T. I., & Prossnitz, E. R.
- Venue
- Nature Chemical Biology
- Published
- 2009-05-03
- Volume
- 5
- Issue
- 6
- Pages
- 421-427
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2076908209
- Cited by
- 532
- References
- 42
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.